First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
Conclusion Filanesib provided exposures with acceptable tolerability and evidence of target-specific pharmacodynamic effects.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Filgrastim | Investigational New Drugs | Neulasta | Neupogen | Neurology | Study | Toxicology